Table 2:

Factors associated with IVH Expansion among Patients Enrolled in the CLEAR III Trial

Covariates	Univariable Analysis		Multivariable Analysis
	OR (95% CI)	P value	OR (95% CI)	P value
Age, per year increase	1.02 (1.01–1.04)	0.02	1.01 (0.99–1.03)	0.39
Female	0.85 (0.57–1.25)	0.41	1.29 (0.83–2.02)	0.26
Black race	0.68 (0.43–1.05)	0.08	0.87 (0.52–1.46)	0.60
Hypertension	1.48 (0.92–2.38)	0.10	1.28 (0.74–2.23)	0.38
Hyperlipidemia	0.73 (0.25–2.18)	0.56
Prior anticoagulant use	2.01 (1.09–3.70)	0.02	1.50 (0.72–3.13)	0.28
Prior antiplatelet use	1.26 (0.81–1.96)	0.31
Glasgow Coma Scale at screening	0.89 (0.83–0.93)	<0.001
ICH location
Lobar	Reference
Deep	1.01(0.53–1.94)	0.97
Primary IVH	1.22 (0.51–2.92)	0.66
Thalamic ICH	1.40 (0.92–2.10)	0.11	1.68 (1.01–2.79)	0.04
Baseline IVH volume, per 1 mL	0.99 (0.97–1.03)	0.27
Baseline ICH volume, per 1 mL	1.01 (0.98–1.04)	0.36	1.04 (1.01–1.08)	0.01
Ictus to stability CT scan time, per 1 hour increase	0.98 (0.96–0.99)	0.01	0.71 (0.54–0.94)	0.02
ICH expansion	5.2 (3.32–8.10)	<0.001	6.63 (3.92–11.24)	<0.001
Intraventricular alteplase use	0.95 (0.64–1.42)	0.80
Admission systolic blood pressure	0.99 (0.97–1.01)	0.74

Abbreviations: CI, confidence interval; CT, computed tomography; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; OR: Odds ratio; P value <0.05 was considered significant